New study reveals path to better outcomes through faster, more accurate biomarker testing

A landmark Canadian study is calling attention to urgent gaps in biomarker testing for non-small cell lung cancer, revealing a clear path to better patient outcomes and more equitable access to life-saving care across the country.

Published in JTO Clinical and Research Reports, the study was developed through the Canadian Pathology Quality Assurance end-to-end quality assurance (EQA) program. The Advanced Diagnostics team at Osler led this cross-disciplinary effort which examined biomarker testing practices at 13 Canadian laboratories.

Biomarker tests are essential for guiding personalized cancer treatment. However, the study found inconsistencies in testing turnaround times and accuracy, which can impact effective care. Among the results, turnaround times ranged from five to 57 days, with only 15% of labs meeting the national two-week standard. Nearly 30% of labs exceeded 30 days for turnaround. The average turnaround time for biomarker results was 22.5 days, which is far above the recommended 10 working days. These delays can lead to missed opportunities for targeted treatments and could cause poorer health outcomes overall for patients.

Regional disparities also emerged as a major concern. Laboratories in some areas struggled with limited resources and infrastructure, making it difficult to meet national benchmarks. As a result, access to high-quality diagnostics and timely treatment varies significantly across the country.

Recommendations for action:

• Adopt comprehensive quality assurance programs: Expand EQA programs to evaluate not only technical accuracy but also turnaround times and report clarity.
• Reduce turnaround times: Aim for biomarker results within 10 working days, and review workflows for labs exceeding 30-day turnaround times.
• Streamline reporting: Use integrated, concise reports with clear language (not just genetic nomenclature) and highlight critical findings and treatment implications.
• Expand testing capacity: Address regional disparities in access to testing by expanding laboratory infrastructure and capacity.
• Support continuous improvement: Implement regular external evaluations to drive ongoing quality improvement.

“As pathologists and clinicians, we must address the important issues identified in this study,” said Dr. Brandon Sheffield, Pathologist and Researcher, Osler Research Institute for Health Innovation. “By bringing these results to light, we aim to support meaningful changes in the Canadian biomarker testing landscape.”

This study is an opportunity to ensure that, in Canada, every patient, regardless of geography, receives fast, accurate cancer diagnostics.